Clinical Scorecard: Assessment of a new device for cryoprevention of oral mucositis: results from a randomized, blinded, multicenter, phase 3 trial

At a Glance

Key Highlights

• OM affects up to 80% of patients receiving high-dose chemotherapy with HSCT and leads to significant clinical complications including infection risk and treatment interruptions
• Conventional cryotherapy with ice chips reduces OM incidence but has limited clinical use due to adverse reactions and infection concerns from waterborne microorganisms
• This trial compared standard ice chip cryotherapy with a novel intraoral cooling device (ICD) providing controlled water circulation at 8°C to improve tolerability and clinical outcomes

Guideline-Based Recommendations

Diagnosis

• Assess oral mucositis using the Oral Mucositis Assessment Scale (OMAS) grading ulceration (0–3) and erythema (0–2) at multiple oral sites
• Perform assessments three times weekly from admission until discharge or day +28 post-transplant
• Use peak OMAS-total score during care for clinical evaluation

Management

• Initiate cryotherapy 30 minutes prior to chemotherapy infusion and continue during and 30 minutes after infusion
• Use either ice chips or an intraoral cooling device for cryoprevention
• For multiple myeloma, apply one 1.5-hour cooling session; for lymphoma, apply 1–2 sessions daily for 5–6 days depending on chemotherapy regimen

Monitoring & Follow-up

• Monitor patient tolerability and adverse reactions using structured questionnaires after each cooling session
• Ensure blinded assessment of OM severity by trained oral medicine specialists to maintain objectivity

Risks

• Ice chips may cause chills, nausea, and sharp dental pain reducing patient adherence
• Potential risk of infection from microorganisms in tap water used to produce ice chips in immunocompromised patients
• Cryotherapy should be carefully supervised to avoid adverse reactions and ensure patient safety

Patient & Prescribing Data

Adult patients with multiple myeloma or lymphoma undergoing high-dose chemotherapy prior to autologous stem cell transplantation

Cryotherapy with either ice chips or an intraoral cooling device is effective for OM prevention; the ICD offers controlled cooling with potentially improved tolerability and reduced infection risk

Clinical Best Practices

• Use randomized, blinded protocols to evaluate cryotherapy interventions in OM prevention
• Train oral medicine specialists in standardized OM assessment scales to ensure reproducibility and reliability
• Inform patients thoroughly about cryotherapy procedures and monitor adherence and tolerability closely
• Prefer closed-system intraoral cooling devices over ice chips to minimize infection risk in immunocompromised patients

References

• Oral mucositis incidence and impact
• Cryotherapy mechanism of action
• Clinical trial protocol and statistical analysis plan